Dana Blankenhorn

Dana Blankenhorn

InvestorPlace Contributor

Expertise: Technology, Biotech, Renewable energy

Education: M.S,J. Northwestern (Medill School) 1978; B.A. Rice University, History and Political Science 1977

Awards & Accomplishments: Tech reporter since 1982, Freelance since 1983, on Internet since 1985. Created first online coverage of Internet with a magazine, Interactive Age, 1994 Co-wrote BBS Systems for Business in 1991, Wrote Guide to Field Computing in 1992 Wrote technology history now called "Living with Moore's Law" in 2001, 2010, 2021 Author of over a dozen books, both fiction and non-fiction

About Dana:
Dana Blankenhorn has been a financial journalist since 1978, a technology journalist since 1982, and an Internet journalist since 1985. He writes a Substack newsletter, Facing the Future, which covers technology, markets, and politics.

He has written a half-dozen technology books, several novels available at the Amazon Kindle store, and covered beats ranging from education to e-commerce, and from open source to renewable energy. He lives in Atlanta.

Recent Articles

Twilio Is Talking a Tech Turnaround

By Dana Blankenhorn, InvestorPlace Contributor

Twilio continues to grow rapidly as its APIs prove its value. Now if it can just turn a profit, TWLO stock will soar.

Warner Brothers Discovery Stock Is a Speculative Buy At Best

By Dana Blankenhorn, InvestorPlace Contributor

WBD stock is now the most interesting stock in media, but whether it's actually worth buying is speculative at best.

Legal Marijuana Isn’t Happening Soon, So Skip Sundial Growers

By Dana Blankenhorn, InvestorPlace Contributor

SNDL stock has lost 90% of its value as the move to federally legalize pot in the U.S. has stalled out, and it's not going anywhere soon.

Cloudflare Shows the Perils of Buying Growth

By Dana Blankenhorn, InvestorPlace Contributor

There's nothing wrong with Cloudflare, but NET stock was overpriced in a world where you can make money at lower risk by lending it.

Camber Energy Is Going Nowhere Fast

By Dana Blankenhorn, InvestorPlace Contributor

CEI stock rose last fall on a short squeeze, and more recently on rising oil prices. But it's not an investment.

Novavax: The Party’s Over

By Dana Blankenhorn, InvestorPlace Contributor

Novavax made its vaccine in the traditional way and with an adjuvant to let it cover more people. But people still seem to prefer mRNA vaccines.

ChargePoint Is Waiting for the Market to Happen

By Dana Blankenhorn, InvestorPlace Contributor

ChargePoint has lined up capital for an EV charging market that won't exist in the U.S. for several years. CHPT stock isn't going anywhere.

Lumen: Dividends Through Liquidation

By Dana Blankenhorn, InvestorPlace Contributor

Lumen is descended from US West, the old Baby Bell company that sold its cellular patrimony in 1997.

What Centene’s Next Era in Managed Care Looks Like

By Dana Blankenhorn, InvestorPlace Contributor

Neidorff built Centene through Medicaid contracts and strict cost controls. His successor is under pressure to increase margins.

Biogen’s Aduhelm Crashes the Biotech Sector

By Dana Blankenhorn, InvestorPlace Contributor

Aduhelm is an Alzheimer's treatment, not a cure. Its quick approval and high price have set off pushback on the whole FDA and Medicare drug process.

Load More